(Q38307958)

2 September 2017

1 reference

title

Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy (English)

1 reference

acute decompensated heart failure

2 September 2017

1 reference

1 reference

4

Hans L Hillege

1 reference

2 September 2017

6

Adriaan A Voors

1 reference

2 September 2017

Jozine M ter Maaten

1

1 reference

2 September 2017

Mattia A E Valente

series ordinal

2

1 reference

2 September 2017

Kevin Damman

series ordinal

3

1 reference

2 September 2017

Gerjan Navis

series ordinal

5

1 reference

2 September 2017

language of work or name

English

0 references

publication date

6 January 2015

1 reference

Nature Reviews Cardiology

2 September 2017

published in

1 reference

2 September 2017

volume

12

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

184-192

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

2 September 2017

1 reference

Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Diuretic therapy and resistance in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Diuretic response in acute heart failure: clinical characteristics and prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Hormones and hemodynamics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

The role of the renin-angiotensin-aldosterone system in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Aldosterone in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Aldosterone 'escape' vs 'breakthrough'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Mechanisms of renal hyporesponsiveness to ANP in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Evidence for functional heterogeneity of circulating B-type natriuretic peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Adenosine and kidney function: potential implications in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

The cardiorenal syndrome in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Renal function, neurohormonal activation, and survival in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Importance of venous congestion for worsening of renal function in advanced decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

The physiologic basis of diuretic synergism: its role in treating diuretic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Effects of metolazone in man: Comparison with chlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Albuminuria in chronic heart failure: prevalence and prognostic importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

The added-up albumin enhances the diuretic effect of furosemide in patients with hypoalbuminemic chronic kidney disease: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Blood urea nitrogen and serum creatinine: not married in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Hemoconcentration-guided diuresis in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Urinary composition during decongestive treatment in heart failure with reduced ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Torasemide in chronic heart failure: results of the TORIC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Continuous versus intermittent infusion of furosemide in acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Diuretic strategies in patients with acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Clarification of the site of action of chlorothiazide in the rat nephron

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Combination diuretic treatment in severe heart failure: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Acetazolamide: a forgotten diuretic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind st

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Extracorporeal ultrafiltration for the treatment of overhydration and congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Ultrafiltration in decompensated heart failure with cardiorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Urodilatin binds to and activates renal receptors for atrial natriuretic peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Diuretic resistance predicts mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Responsiveness to loop diuretics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Pathophysiology of sodium and water retention in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Bumetanide and furosemide in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Transcapillary escape rate of albumin and right atrial pressure in chronic congestive heart failure before and after treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Renal secretion of [35-S]furosemide and depression by albumin binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

The organic anion transporter family: from physiology to ontogeny and the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Voltage-driven p-aminohippurate, chloride, and urate transport in porcine renal brush-border membrane vesicles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Mechanism of impaired natriuretic response to furosemide during prolonged therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Factors modifying the early nondiuretic vascular effects of furosemide in man. The possible role of renal prostaglandins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Outcomes of furosemide-mannitol infusion in hospitalized patients with heart failure: an observational single-center cohort study of 122 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Aldosterone in Congestive Heart Failure: Analysis of Determinants and Role in Sodium Retention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

The supra-additive natriuretic effect addition of quinethazone or bendroflumethiazide during long-term treatment with furosemide and spironolactone. Permutation trial tests in patients with congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Short-Term Effects of Hypertonic Saline Solution in Acute Heart Failure and Long-Term Effects of a Moderate Sodium Restriction in Patients With Compensated Heart Failure With New York Heart Association Class III (Class C) (SMAC-HF Study)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Sequential nephron blockade breaks resistance to diuretics in edematous states

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.215

Co-administration of albumin-furosemide in patients with the nephrotic syndrome.

31 March 2020

1 reference

12 December 2020

Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment

1 reference

12 December 2020

Potassium restoration in hypertensive patients made hypokalemic by hydrochlorothiazide

1 reference

12 December 2020

Use of inhibitors in physiological studies of carbonic anhydrase

1 reference

12 December 2020

Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone.

1 reference

12 December 2020

Response of the kidney to furosemide. I. Effects of salt intake and renal compensation

1 reference

12 December 2020

Osmotic and nonosmotic control of vasopressin release

1 reference

12 December 2020

Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1.

1 reference

12 December 2020

Pharmacodynamics of the diuretic effects of aminophylline and acetazolamide alone and combined with furosemide in normal subjects

1 reference

12 December 2020

Osmoregulation and control of vasopressin secretion in healthy humans

1 reference

12 December 2020

10.1038/NRCARDIO.2014.215

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1034261046

0 references

1 reference